- Associated Press•3 hours ago
On a per-share basis, the Bothell, Washington-based company said it had a loss of 42 cents. The results missed Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment ...
- Business Wire•3 hours ago
Seattle Genetics, Inc. , a global biotechnology company, today reported financial results for the first quarter ended March 31, 2017. The company also highlighted ADCETRIS commercialization and clinical development accomplishments, vadastuximab talirine and enfortumab vedotin activities, as well as progress with its pipeline of antibody-drug conjugates and other proprietary programs.
- Accesswire•7 hours ago
NEW YORK, NY / ACCESSWIRE / April 27, 2017 / Seattle Genetics, Inc. (NASDAQ: SGEN) will be discussing their earnings results in their Q1 Earnings Call to be held April 27, 2017 at 4:30 PM Eastern Time. ...
SGEN : Summary for Seattle Genetics, Inc. - Yahoo Finance
Seattle Genetics, Inc. (SGEN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||68.26 x 1000|
|Ask||70.48 x 100|
|Day's Range||66.61 - 68.68|
|52 Week Range||32.40 - 75.36|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-68.60|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|